Edgewise Therapeutics reports Q4 2024 net loss of $39.7M; pipeline milestones on track

Edgewise Therapeutics, Inc.

Net loss $39.7M ($0.42 per share) for Q4 2024; cash and equivalents $470.2M as of Dec 31, 2024.
Completed GRAND CANYON enrollment (175 adults) for sevasemten in Becker; topline data expected Q4 2026.
Positive Phase 2 CANYON topline results for sevasemten in Becker; plan to discuss FDA filing in H1 2025.
On track to report CIRRUS-HCM Phase 2 data in Q1 2025 and LYNX/FOX Duchenne data in H1 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.